Cystatin C With Glomerular Filtration Rate, Estimated (eGFR)

CPT: 82610
Updated on 12/23/2024
Print Share

Synonyms

  • Cystatin C
  • eGFR
  • Estimated Glomerular Filtration Rate
  • GFR, Estimated

Test Includes

Cystatin C; eGFR calculation


Expected Turnaround Time

2 - 5 days


Related Documents


Specimen Requirements


Specimen

Serum (preferred) or plasma

Serum or plasma

Serum (preferred) or plasma


Volume

1 mL

0.5 mL

1 mL


Minimum Volume

0.5 mL


Container

Gel-barrier tube or green-top (heparin) tube

Red-top tube, gel-barrier tube, or green-top (heparin) tube

Gel-barrier tube or green-top (heparin) tube


Collection

If green-top (heparin) tube is used, separate plasma from red blood cells and transfer plasma to a transfer tube.

Separate serum or plasma from red blood cells.

If green-top (heparin) tube is used, separate plasma from red blood cells and transfer plasma to a transfer tube.


Storage Instructions

Room temperature


Stability Requirements

TemperaturePeriod
Room temperature7 days at 15°C to 25°C (stability provided by manufacturer or literature reference)
Refrigerated7 days at 2°C to 8°C (stability provided by manufacturer or literature reference)
Frozen6 months at -20°C (stability provided by manufacturer or literature reference)
Freeze/thaw cyclesStable x1 (stability provided by manufacturer or literature reference)

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

TemperaturePeriod
Room temperature7 days at 15°C to 25°C (stability provided by manufacturer or literature reference)
Refrigerated7 days at 2°C to 8°C (stability provided by manufacturer or literature reference)
Frozen6 months at -20°C (stability provided by manufacturer or literature reference)
Freeze/thaw cyclesStable x1 (stability provided by manufacturer or literature reference)

Patient Preparation

Overnight fasting is preferred.


Causes for Rejection

Specimen other than serum or heparinized plasma; grossly hemolyzed (>1,000 mg/dL Hgb) samples; excessive turbidity and clots in samples


Test Details


Use

Since it is formed at a constant rate and freely filtered by the healthy kidney, cystatin C is a good marker of renal function. Serum concentrations of cystatin C are almost totally dependent on glomerular filtration rate (GFR). A reduction in GFR causes a rise in the concentration of cystatin C.1,2

Can be used as a confirmatory test for the diagnosis of chronic kidney disease (CKD) in patients with a decreased GFR as estimated from creatinine.

Data suggests that 3.6% of U.S. adults would be classified as having CKD solely on the basis of a creatinine-based GFR estimate of 45 to 59 mL per minute per 1.73m2. A strategy of measuring cystatin C when the creatinine-based estimate is in this range and then reestimating GFR with the use of both these markers could correctly reclassify a substantial proportion of such patients as not having CKD and not being at high risk.

Can also be used to screen for CKD among persons who have a creatinine-based GFR estimate of 60 to 74 mL per minute per 1.73m2 without albuminuria (10.9% of US adults) or to obtain a more accurate estimation of GFR in patients with muscle wasting or chronic illness.


Limitations

Cystatin C has not been shown to be affected by factors such as muscle mass and nutrition, factors which have been demonstrated to affect creatinine values. In addition, a rise in creatinine does not become evident until the GFR has fallen by approximately 50%.


Methodology

Turbidimetric (directly traceable to ERM-DA471/IFCC, the international standard reference material)


Additional Information

The estimated glomerular filtration (GFR) provides an assessment of the filtering capacity of the kidney. The eGFR is calculated from a serum cystatin C using the CKD-EPI equation, 2012.3


Footnotes

1. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38 Suppl 1: S20-7.1284235
2. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000 Jul;36(1):29-34.10873868
3. National Kidney Foundation. CKD-EPI Cystatin C Equation (2012). National Kidney Foundation web site. https://www.kidney.org/content/ckd-epi-cystatin-c-equation-2012. Accessed December 2020.

References

Grubb A, Blirup-Jensen S, Lindstrom V, et al. First certified reference material for cystatin C in human serum ERM- DA471/IFCC. Clin Chem Lab Med. 2010 Nov;48(11):1619-1621.21034257
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-29.22762315
Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011 Jan;22(1):147-155.21164029
Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011 Apr 20;305:1545-1552.21482744
Stevens LA, Padala S, Levey AS. Advances in glomerular filtration rate-estimating equations. Curr Opin Nephrol Hypertens. 2010 May;19(3):298-307.20393287

LOINC® Map

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf